Trio Genome Sequencing Finds Genetic Causes in Most Kids Born Small Who Never Catch Up

Children born small for gestational age usually grow rapidly in the first months of life, a phenomenon clinicians call catch-up growth. But a substantial minority never catch up, and some of these children also carry anomalies affecting multiple organ systems. A new study published in BMC Pediatrics suggests that for this high-risk subgroup, the answer often lies in the genome—and that sequencing the whole family, not just the child, can find it.

Researchers at Dongguan Maternal and Child Health Care Hospital in China retrospectively analyzed 99 children born small for gestational age who had either failed to show catch-up growth, presented with multisystem anomalies, or both. Using trio-based whole-exome sequencing, in which the affected child and both parents are sequenced together, the team searched for the genetic roots of these children’s conditions. The results were striking: a confirmed molecular diagnosis was established in 59 of the 99 children, a diagnostic yield of 59.6 percent.

Trio-based whole-exome sequencing works by capturing and reading the protein-coding portions of the genome—the exome—in all three members of a family. Because the parents’ sequences are available for comparison, scientists can determine whether a suspicious variant was inherited from a carrier parent or arose spontaneously in the child. This segregation analysis is critical for interpreting variants correctly, since the same DNA change can be harmless in one context and disease-causing in another.

The study’s methodology went beyond simple sequence analysis. In addition to examining single-nucleotide and small insertion-deletion variants, the researchers mined the sequencing read-depth data to infer copy-number variants—large deletions or duplications of chunks of chromosomes that conventional exome pipelines often miss. Sequence variants were confirmed by Sanger sequencing, the older but highly accurate method of reading individual DNA fragments. Variants were then classified using the standards developed by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology for sequence variants, and the ACMG/ClinGen criteria for copy-number variants.

Only pathogenic or likely pathogenic findings whose inheritance pattern fit the family data were counted as molecular diagnoses. This conservative approach matters in clinical genetics, where over-interpretation of ambiguous variants can lead to false diagnoses. The team also identified four variants that remained classified as variants of uncertain significance—changes that could not be confidently labeled benign or disease-causing and therefore did not count toward the diagnostic yield.

Breaking down the 59 diagnoses, the researchers found considerable diversity in the underlying genetic architecture. Monogenic disorders—single-gene defects—accounted for the largest share, explaining 44 children, or 74.6 percent of the diagnosed cases. Copy-number variants explained 13 children, or 22.0 percent. Notably, two children received dual diagnoses, carrying both a disease-causing sequence variant and a pathogenic copy-number variant, a reminder that a single genetic explanation is not always sufficient.

The diagnostic yield differed meaningfully between the two clinical presentations. Among children with isolated failed catch-up growth—those born small who never caught up but had no other anomalies—trio-WES produced a diagnosis in 52.9 percent of cases, or 9 of 17 children. Among children with multisystem anomalies, the yield rose to 61.0 percent, or 50 of 82 children. The higher yield in the multisystem group aligns with genetic principles: when developmental disturbances affect multiple organ systems, a shared underlying genetic cause becomes more likely, and the genome search has more clinical features to anchor interpretations.

The clinical implications are considerable. A molecular diagnosis does more than attach a name to a condition. It can redirect management toward condition-specific surveillance and treatment, inform parents about recurrence risks for future pregnancies, and spare families a prolonged diagnostic odyssey of repetitive and often invasive testing. For children born small for gestational age, identifying a specific genetic syndrome may reveal risks—such as endocrine dysfunction, renal anomalies, or tumor predisposition—that would otherwise be missed. Genetic counselling grounded in an identified inheritance model allows clinicians to tell parents precisely whether the condition could recur in a subsequent child.

The authors are careful to draw boundaries around their conclusions. The 99 children in this study were not a random sample of all children born small for gestational age; they were a clinically selected, high-risk subgroup who had already raised concern because of persistent growth failure or anomalies affecting multiple systems. The researchers explicitly caution that the 59.6 percent diagnostic yield should not be generalized to the overall SGA population, most of whom are simply constitutionally small and healthy. Applying expensive genome-wide testing to every child born small, without clinical red flags, would produce far lower yields and risk incidental and ambiguous findings.

Still, the study adds to a growing body of evidence that trio-based genomic sequencing should be considered early rather than late in the evaluation of children with unexplained growth failure and congenital anomalies. As sequencing costs continue to fall and analytical tools improve—including methods that detect copy-number variants from exome data without separate chromosome microarray testing—the case for a single comprehensive genetic test at the start of the diagnostic journey grows stronger. For families facing the anxiety of a child who is not growing as expected, a faster path to answers may now be within reach.

Subject of Research: Use of trio-based whole-exome sequencing to diagnose genetic disorders in children born small for gestational age with failed catch-up growth or multisystem anomalies

Article Title: Clinical application of trio-based whole-exome sequencing in children born small for gestational age with failed catch-up growth or multisystem anomalies

Article References: Jiang, Z., Zhong, X., Lin, P., Yan, T., He, W., Guo, L., Xie, Y., Yuan, H., & Cheng, S. (2026). Clinical application of trio-based whole-exome sequencing in children born small for gestational age with failed catch-up growth or multisystem anomalies. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07633-5

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07633-5

Keywords: small for gestational age, trio whole-exome sequencing, failed catch-up growth, multisystem anomalies, molecular diagnosis, copy-number variants, genetic counselling, pediatrics, next-generation sequencing, rare variants, clinical genetics, Clinical